Disclaimer

The information on this website is being made available by Oxford Cannabinoid Technologies Holdings plc ("OCTH") in good faith and for information purposes only. Please read this notice carefully - it applies to all persons who view this Website. Please note that this notice may be altered or updated. You should therefore read it in full each time you visit this Website.

The information contained on this Website is not comprehensive and much of it is historical. No reliance may be placed for any purpose whatsoever on the, or the suitability of the shares of OCTH for any prospective investor and OCTH, its directors, shareholders, advisers, affiliates, agents, representatives and employees assume no responsibility to you or any third party for the consequences of any errors or omissions. Neither OCTH, its directors, shareholders, advisers, affiliates, agents, representatives nor employees accept any liability for any direct or indirect or consequential loss or damages of any kind resulting from any use of this Website or any information contained on it.

Some of the statements contained on this Website and in documents accessed through this Website may be forward looking statements. Actual results may differ from those expressed in such statements, depending on a variety of factors. The past performance of OCTH or its shares cannot be relied on as a guide to future performance. The price of the shares may go down as well as up and it may be that investors do not recoup the amount originally invested.

This Website and the information on it does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in OCTH, nor shall it (or any part of it) or the fact of its distribution form the basis of, or be relied on in connection with or act as an inducement to enter into any contract or commitment therefor and any decisions you make based on the information contained on this Website are your sole responsibility having, where appropriate, taken independent advice as to the investment decision and any laws or regulations applicable to such investment decision.

The information contained in this section of the Website is not directed at, nor is it intended for access by, persons located or resident in the United States, Australia, Canada, the Republic of South Africa, or Japan or any other jurisdiction in which it may be unlawful to receive or view such information. If you are not permitted to view the information (or are in any doubt as to whether you are permitted to view the information), please exit this Website. Any shares of OCTH referred to in the information on this Website have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended. Such shares have also not been registered under the applicable securities laws of Australia, Canada, the Republic of South Africa or Japan and may not be offered or sold in Australia, Canada, the Republic of South Africa or Japan or any other jurisdiction if to do so would constitute a violation of the relevant laws of, or require registration thereof in, such jurisdiction.

OCTH, its directors, shareholders, advisers, affiliates, agents, representatives and employees (whether or not involved in creating, producing, maintaining or delivering this Website) exclude all liability and responsibility for any amount or kind of loss or damage that may result to you or a third party in connection with this Website in or the information contained on it.

By clicking "Accept" you accept you have read the terms of this Important Notice.

Accept Decline

Skip Navigation LinksHome   >   Investors   >   Financial Calendar

Financial Calendar

Upcoming

2023  
AGM

28 September 2023

The Company's AGM will be held at the offices of Penningtons Manches Cooper LLP at 125 Wood Street, London EC2V 7AW on 28 September 2023 at 11.00a.m.

 

The Company encourages shareholders the opportunity to ask the Board questions in advance of the meeting by emailing the Company Secretary Rob Bennett at rob@oxcantech.com.

 

Notice of Meeting

Form of Proxy

Half Year End 31 October 2023

 

Previous dates

2021  
Year-end              31 May 2021
Half-year end 30 Nov 2021
2022  
Half year results 22 February 2022
Analyst Briefing

22 February 2022

Analysts interested in attending should contact Walbrook PR by emailing oxcantech@walbrookpr.com or by calling 020 7933 8780.

Investor Presentation

22 February 2022

Investors can sign up to Investor Meet Company for free and add to meet Oxford Cannabinoid Technologies Holdings plc via: https://www.investormeetcompany.com/oxford-cannabinoid-technologies-holdings-plc/register-investor

Shares & AJ Bell Investor Evening

23 February 2022

John Lucas, CEO, will be presenting at the Shares and AJ Bell investor evening webinar on Wednesday 23 February 2022, covering the Company's half year results and future prospects. 

https://www.sharesmagazine.co.uk/events/event/shares-investor-webinar-230222

Year-end

30 April 2022

Investor Meet Company Q&A Session

30 May 2022

Questions can be submitted pre-event via the 'Investor Meet Company' dashboard up until 9:00 a.m. on Friday 27 May 2022 or at any time during the live presentation. Investors can sign up to Investor Meet Company for free by clicking here

Annual Results 25 July 2022
Analyst Briefing

Analyst Briefing, 2:00pm, 25 July 2022

Analysts interested in attending should contact Walbrook PR by emailing oxcantech@walbrookpr.com or by calling 020 7933 8780.

 

Investor Presentation

Investor Presentation, 4.30pm, 25 July 2022

A live online presentation via the Investor Meet Company platform will also be held at 4.30pm (BST) today, which is open to all existing and potential shareholders. Questions can be submitted at any time during the live presentation.

Annual General Meeting

28 September 2022

Half Year End 31 October 2022
Half Year Results 23 January 2023
Investor Presentation

23 January 2023

Investors can sign up to Investor Meet Company for free and add to meet Oxford Cannabinoid Technologies Holdings plc via: https://www.investormeetcompany.com/oxford-cannabinoid-technologies-holdings-plc/register-investor

Analyst Briefing

23 January 2023

Analysts interested in attending should contact Walbrook PR by emailing oxcantech@walbrookpr.com or by calling 020 7933 8780.

Year End 30 April 2023
Investor Presentation

19 July 2023

 

OCTP will host a live presentation and Q&A via the Investor Meet Company platform at 4.00pm on Wednesday 19 July 2023, open to all existing and potential shareholders.

Recently appointed Chief Medical Officer, Dr Tim Corn and Chief Scientific Officer, Dr Valentino Parravicini,‚Äč will discuss developments across the Company's portfolio.

Investors can sign up to Investor Meet Company for free and add to meet Oxford Cannabinoid Technologies Holdings plc via: https://www.investormeetcompany.com/oxford-cannabinoid-technologies-holdings-plc/register-investor

Annual Results 31 August 2023
Analyst Briefing

Analyst Briefing, 9:30am, 31August 2023

Analysts interested in attending should contact Acuitas Communications by emailing oct@acuitascomms.com.

Investor Presentation

Investor Presentation, 1.30pm, 31 August 2023

A live online presentation via the Investor Meet Company platform will be held at 1.30pm, which is open to all existing and potential shareholders. Questions can be submitted at any time during the live presentation.

https://www.investormeetcompany.com/oxford-cannabinoid-technologies-holdings-plc/register-investor